logo

For the Inventor, By the Inventor

Fremont, CA, United States of America

Amgen Fremont Inc.


USPTO Granted Patents = 78

% Expired Patents = 53.8



Forward Citations = 1,326

Loading Chart...
Loading Chart...

147 inventors (with patents filed for the assignee):

goldMedal Larry L Green (34 out of 71 patents)

silverMedal Jose Corvalan (26 out of 34 patents)

bronzeMedal Xiao-Chi Jia (22 out of 57 patents)

4.  Ian Nevin Foltz (20 out of 68 patents)

5.  Jaspal Singh Kang (17 out of 41 patents)

6.  Vahe Bedian (15 out of 29 patents)

7.  Xiao Feng (15 out of 22 patents)

8.  Orit Foord (14 out of 78 patents)

9.  Scott L Klakamp (14 out of 16 patents)

10.  Chadwick Terence King (13 out of 59 patents)

11.  Bruce Alan Keyt (11 out of 43 patents)

12.  Palaniswami Rathanaswami (11 out of 14 patents)

13.  Qiaojuan Jane Su (11 out of 18 patents)

14.  Mary Haak-Frendscho (11 out of 47 patents)

15.  C Geoffrey Davis (11 out of 15 patents)


Core Competencies:
CTLA-4
Epidermal Growth Factor Receptor
Monoclonal Antibodies
Cancer Treatments
M-CSF
Antibody Engineering
Tumor Necrosis Factor
Insulin-Like Growth Factor
CD40
OPGL
TGF-Beta
Myostatin

78 patents:

1. 11492411 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2022-11-08),
2. 10508153 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2019-12-17),
3. 10280219 - Antibodies to M-CSF (2019-05-07),
4. 10259872 - Antibodies to MAdCAM (2019-04-16),
5. 10118968 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2018-11-06),
6. 9963508 - Human monoclonal antibodies to CTLA-4 (2018-05-08),
7. 9718883 - Antibodies to M-CSF (2017-08-01),
8. 9580503 - Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof (2017-02-28),
9. 9328169 - Human antibodies that bind human MAdCAM (2016-05-03),
10. RE45847 - Antibodies to MAdCAM (2016-01-18),
11. 9238691 - Nucleic acids encoding antibodies to CCR2 (2016-01-19),
12. 9234041 - Antibodies to insulin-like growth factor I receptor (2016-01-12),
13. 9221915 - Human monoclonal antibodies to activin receptor-like kinase-1 (2015-12-29),
14. 9096672 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2015-08-04),
15. 9085624 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2015-07-21),
Company Overview
Amgen Fremont Inc., located in Fremont, California, is a prominent biotechnology company specializing in the development and manufacturing of monoclonal antibodies. The organization focuses on innovative cancer treatments, leveraging advanced technologies related to CTLA-4, Epidermal Growth Factor Receptor, and Tumor Necrosis Factor. With expertise in antibody engineering and related therapeutic areas, Amgen aims to address significant medical needs through its cutting-edge research and development efforts in the biopharmaceutical sector.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

78 Patents

#35 in Fremont, CA

#1,099 in California

#4,745 in US

#9,688 in the World

Fremont, CA (US)
Fremont, CA, United States of America

Amgen Fremont Inc.

Forward Citations = 1,326

147 inventors:

goldMedal Larry L Green (34 out of 71 patents)

silverMedal Jose Corvalan (26 out of 34 patents)

bronzeMedal Xiao-Chi Jia (22 out of 57 patents)

4.  Ian Nevin Foltz (20 out of 68 patents)

5.  Jaspal Singh Kang (17 out of 41 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Amgen Fremont Inc.. Retrieved from https://idiyas.com/company/amgen-fremont

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…